Replimune Group, Inc is a pioneering biotechnology company based in Woburn, MA, specializing in the development of novel oncolytic immunotherapies. Their transformative therapies are designed to target and kill tumors locally, modify the tumor microenvironment, and stimulate a patient-specific immune response, with a focus on treating difficult-to-treat cancers.
With ongoing clinical trials evaluating the safety and efficacy of their investigational therapies, Replimune aims to provide innovative treatment options for a range of solid tumor cancers, both as standalone treatments and in combination with other immunotherapies.
Generated from the website